Richard,
I'm not sure, but it sounds like you're turning bearish. Just a few
comments on the points you raised in your last post...
1. "No income" will not become the new model. However, for
diseases which have no effective treatment, the FDA may allow the
company to give the drug away prior to its approval. This is good
for the patients, and good for the company since they get good
publicity and can test out their drug. Don't forget how powerful
that "AIDS-patient lobby" is out there. Never before in the history
of pharmaceutical developmenmt has there been such a vocal, political
group of patients. They are helping to push FDA reform, which is
making it easier and quicker for drug companies to get their
product approved.
2. The allergic response seen in one patient out of 7 in the cancer
trials for PN27,1 is not significant IMO. They didn't say how
severe the response was, and they didn't mention if there were
antibodies formed, and if so, whether they were neutralizing.
Considering the absolutely horrible effects of other popular cancer
drugs and treatments (i.e., chemo and radiotherapy), a little
allergic response doesn't seem all that bad.
3. PRLN is not a "Johnny come lately" with "another drug" therapy.
If have been following many, many biotechs, and Paracelsian is the
most unusual company I have seen (I guess this can be good or bad).
The compounds they are studying are unusual, their approach is
unusual, and even their strategy (i.e., selling PN355,1 as a dietary
suppliment) is unique.
As for the current stock price, hovering around $3? I, and my broker,
do not know. Perhaps it is simply part of the ebb and flow of the
stock market. Notice that when the market looked weak, PRLN looked
strong, and now the reverse is true. I would only get concerned if
the price dove on a large volume, and even then I probably would not
sell. This WOULD be a good time for another of those 15-20 press
releases to come out!
Rick |
